Product Name
AIF peptide
Catalog Number
GTX27871
Product Description:
AIF ( N - term ) peptide ( human )
Application Note:
The peptide is used for blocking the antibody activity of AIF. It usuallyblocks the antibody activity completely in Western blot by incubating the peptide with equalvolume of antibody for 30 min at 37°C
Background:
Apoptosis is characterized by several morphological nuclear changes including chromatin condensation and nuclear fragmentation. These changes are triggered by the activation of members of caspase family, caspase activated DNase, and several novel proteins. A novel gene, the product of which causes chromatin condensation and DNA fragmentation, was recently identified, cloned, and designated apoptosis inducing factor (AIF). Like the critical molecules, cytochrome c and caspase-9, in apoptosis, AIF localizes in mitochondria. AIF translocates to the nucleus when apoptosis is induced and induces mitochondria to release the apoptogenic proteins cytochrome c and caspase-9. AIF induces chromatin condensation and large scale DNA fragmentation, which are the hallmarks of apoptosis, of the isolated nucleus and the nucleus in live cells by microinjection and apoptosis stimuli. AIF is highly conserved between human and mouse and widely expressed.
Tested Application:
Blocking
Sequence:
KQKKAALSASEGEE; Amino acids 109 to 122 of human AIF
Purity:
n/a
Storage Instruction:
Store at -20 °C. Stable for one year.
Concentration:
0.2 mg/ml
Storage Buffer:
PBS with 0.1% BSA 0.02% sodium azide pH7.2
Tested Applications:
Blocking
Concentration Unit:
mg/ml
Storage:
Store at -20°C. Stable for one year.
General References:
1. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosisinducingfactor. Nature 1999;397:441-6.
1999
2. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosisinducingfactor. Nature 1999;397:441-6.
1999
|
| Please tell us about your experience or submit a specific inquiry about this product. |
